Sana Biotechnology, Inc.
Edit

Sana Biotechnology, Inc.

http://www.sana.com/
Last activity: 04.11.2024
Active
Categories: BioTechBodyBuildingCauseDeliveryHealthTechHumanITManufacturingPublic
Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy.

Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders.

Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.
Website visits
20.8K /mo.
Mentions
42
Location: United States, Washington, Seattle
Employees: 201-500
Total raised: $2.79B
Valuation: $6.5B
Founded date: 2018

Investors 9

Funding Rounds 4

DateSeriesAmountInvestors
04.02.2021IPO$587.5M-
23.10.2020-$700M-
25.06.2020-$700M-
07.01.2019-$800M-

Mentions in press and media 42

DateTitleDescription
04.11.2024Last week recap: More than 60 tech funding deals worth over €1BLast week, we tracked more than 60 tech funding deals worth over €1 billion, and over 5 exits, M&A transactions, rumours, and related news stories across Europe. The top three industries that raised the most were marketing (€471 million...
20.10.2024Gladia: AI Transcription And Audio Intelligence Company Raises $16 Million (Series A)Gladia, an AI-based transcription and audio intelligence provider, announced it has completed a $16 million Series A funding round. The company will use the funding to develop an end-to-end audio infrastructure, starting with a new real-tim...
18.03.2024Anthropic-backer Menlo Ventures is preparing for a 'gold rush' of AI infrastructure startups. Here's why.Startups Anthropic-backer Menlo Ventures is preparing for a 'gold rush' of AI infrastructure startups. Here's why. Samantha Stokes and Darius Rafieyan 2024-03-18T09:00:01Z Share icon An curved arrow pointing right. Share Facebook Icon The l...
10.10.2023Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn ...-
11.04.2023Tech Moves: Adaptive Biotechnologies COO departing; Sana adds leaders; and moreMark Adams. (Adaptive Photo) — Mark Adams is stepping down as chief operating officer of Adaptive Biotechnologies, the company said today in a regulatory filing. Adams joined the Seattle-based biotech giant more than three years ago. The fi...
10.04.2023Tech Moves: Halo leader departing; Remitly adds board directors; drone vet lands at RantizoPhyllis Campbell (left) and Ryno Blignaut. — Seattle-based fintech company Remitly added two new board members: Ryno Blignaut and Phyllis Campbell. Blignaut is an investor with Silicon Valley venture firm Khosla Ventures and previously serv...
11.01.2022Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR ConstructSEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China and SHANGHAI, Jan. 11, 2022 /PRNewswire/ -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medici...
11.01.2022Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR ConstructSEATTLE, SAN FRANCISCO, SAN JOSE, Calif., NANJING, China, SUZHOU, China and SHANGHAI, Jan. 11, 2022 /PRNewswire/ -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, IASO Bi...
19.10.2021Sage, Bio­gen head to FDA with $3.1B de­pres­sion drug; Sana puts down $50M to tap Beam's CRISPR techWeeks af­ter an­nounc­ing they would drop a pair of stud­ies deemed un­nec­es­sary to file the de­pres­sion drug zu­ra­nolone for ap­proval, Sage and Bio­gen are go­ing for it. Fol­low­ing a pre-NDA meet­ing with the FDA, the part­ners say ...
15.07.2021Catal­ent lands 2 new part­ner­ships, in­clud­ing for glioblas­toma drug; US drops $153M in­to pan­dem­ic pre­pared­nessBack just before the pandemic hit the world in early 2020, Moderna’s shares were trading right around $20 a share. Today, it’s above $250 a share — up 3% this morning — and the market cap has pierced the $100 billion mark. Working solo, the...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In